Literature DB >> 3318495

Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome.

J E Kellow1, L J Miller, S F Phillips, A R Zinsmeister, J W Charboneau.   

Abstract

We compared responses of the gallbladder to graded intravenous infusions of cholecystokinin octapeptide (CCK-OP) in normal controls (n = 8) and patients with irritable bowel syndrome (IBS) with predominant constipation (n = 8) or diarrhea (n = 8). The doses of CCK-OP ranged from subphysiological (negligible contraction of the gallbladder) to supraphysiological (90% contraction of gallbladder and abdominal side effects) amounts. All gallbladders contracted progressively in response to CCK-OP, and a Weibull model (power exponential function) described precisely the gallbladder's response to CCK-OP. Patients with IBS responded differently from normal patients; those with constipation contracted their gallbladders more and those with diarrhea contracted less in response to the peptide. Gallbladders were also stimulated with a high-fat, liquid meal; all patients' gallbladders contracted, but clear differences between groups could not be demonstrated postprandially. The results suggest that the smooth muscle of the gallbladder in IBS has an abnormal sensitivity to CCK-OP, and the results support the concept that IBS can be a generalized abnormality of the smooth muscle of the digestive tract.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318495     DOI: 10.1152/ajpgi.1987.253.5.G650

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

Review 1.  Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain.

Authors:  Amit Rastogi; Adam Slivka; Arthur James Moser; Arnold Wald
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study.

Authors:  M A McNally; G R Locke; A R Zinsmeister; C D Schleck; J Peterson; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2008-08-01       Impact factor: 8.171

3.  Dysmotility of the small intestine in irritable bowel syndrome.

Authors:  J E Kellow; S F Phillips; L J Miller; A R Zinsmeister
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

Review 4.  Intestinal dysmotility and the irritable bowel syndrome.

Authors:  E M Quigley
Journal:  Ir J Med Sci       Date:  1994-12       Impact factor: 1.568

Review 5.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

Review 6.  Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder.

Authors:  D P McKee; E M Quigley
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

Review 7.  Involvement of endogenous CCK and CCK1 receptors in colonic motor function.

Authors:  Gábor Varga; András Bálint; Beáta Burghardt; Massimo D'Amato
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

8.  Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome.

Authors:  Piero Portincasa; Antonio Moschetta; Giuseppe Baldassarre; Donato F Altomare; Giuseppe Palasciano
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter.

Authors:  P R Evans; J F Dowsett; Y T Bak; Y K Chan; J E Kellow
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

10.  Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride.

Authors:  L Marzio; F DiFelice; M G Laico; B Imbimbo; D Lapenna; F Cuccurullo
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.